Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.66 |
| ▸ | FLT1 known ✓ | P17948 | 14/20 | 0.66 |
| ▸ | PDGFRB known ✓ | P09619 | 6/20 | 0.59 |
| ▸ | KIT known ✓ | P10721 | 5/20 | 0.59 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.59 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 2/20 | 0.59 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.59 |
| ▸ | HLA-A | P04439 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | FRK | P42685 | 1/20 | 0.59 |
| ▸ | CDK8 | P49336 | 1/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.59 |
| ▸ | STK3 | Q13188 | 1/20 | 0.59 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.59 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.59 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482081 | 0.95 | KDR (0.69) | KDRFLT1PDGFRBKITFLT4 | |
| Hydrochloric Acid SCHEMBL6474025 | 0.94 | KDR (0.68) | KDRFLT1PDGFRBKITFLT4 | |
| SCHEMBL6474354 | 0.91 | KDR (0.66) | KDRFLT1PDGFRBKITFLT4 | |
| SCHEMBL6479831 | 0.87 | KDR (0.71) | KDRFLT1PDGFRBKITFLT4 | |
| Hydrochloric Acid SCHEMBL6480219 | 0.86 | KDR (0.70) | KDRFLT1PDGFRBKITFLT4 | |
| SCHEMBL6497078 | 0.85 | KDR (0.58) | KDRFLT1PDGFRBKITFLT4 | |
| Vatalanib SCHEMBL6607537 | 0.83 | KDR (0.84) | KDRFLT1PDGFRBKITFLT4 | |
| SCHEMBL6482138 | 0.80 | KDR (0.60) | KDRFLT1PDGFRBKITFLT4 | |
| SCHEMBL6481343 | 0.80 | KDR (0.53) | KDRFLT1PDGFRBKITFLT4 | |
| SCHEMBL6498239 | 0.80 | KDR (1.00) | KDRFLT1PDGFRBKITFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903101-B1 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
| EP-1467736-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1208096-B1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER AG (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2003059354-A2 | ANTI-ANGIOGENESIS COMBINATION THERAPIES COMPRISING PYRIDAZINE OR PYRIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1208096-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2001010859-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-02-15 | — | — | WO | claimed |
| US-6903101-B1 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1208096-B1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER AG (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1208096-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Corporation (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001010859-A1 | SUBSTITUTED PYRIDAZINES AND FUSED PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORPORATION (US) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885PDGFRB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.